181 related articles for article (PubMed ID: 29341069)
1. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB).
Bruckner AL; Fairclough DL; Feinstein JA; Lara-Corrales I; Lucky AW; Tolar J; Pope E
Br J Dermatol; 2018 May; 178(5):1128-1134. PubMed ID: 29341069
[TBL] [Abstract][Full Text] [Related]
2. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).
Rogers CL; Gibson M; Kern JS; Martin LK; Robertson SJ; Daniel BS; Su JC; Murrell OGC; Feng G; Murrell DF
JAAD Int; 2021 Mar; 2():134-152. PubMed ID: 34409361
[TBL] [Abstract][Full Text] [Related]
3. Psychometric Properties of the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa patient score (iscorEB-p): a patient-reported outcome measure.
Salamon G; Strobl S; Field-Werners U; Diem A; Schwieger-Briel A; Pope E
Br J Dermatol; 2024 Jun; 191(1):75-81. PubMed ID: 38261404
[TBL] [Abstract][Full Text] [Related]
4. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
[TBL] [Abstract][Full Text] [Related]
5. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Loh CC; Kim J; Su JC; Daniel BS; Venugopal SS; Rhodes LM; Intong LR; Law MG; Murrell DF
J Am Acad Dermatol; 2014 Jan; 70(1):89-97.e1-13. PubMed ID: 24355263
[TBL] [Abstract][Full Text] [Related]
6. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool.
Schwieger-Briel A; Chakkittakandiyil A; Lara-Corrales I; Aujla N; Lane AT; Lucky AW; Bruckner AL; Pope E
Pediatr Dermatol; 2015; 32(1):41-52. PubMed ID: 24650374
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and clinical severity in people with epidermolysis bullosa - A proposal for assessing nutritional compromise by body mass index (Birmingham Epidermolysis Bullosa Severity Score).
Togo CCG; Zidório APC; Sá NM; Dutra ES
Nutr Hosp; 2024 Apr; 41(2):400-408. PubMed ID: 38149521
[TBL] [Abstract][Full Text] [Related]
8. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
[TBL] [Abstract][Full Text] [Related]
9. Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score: a multicenter development and reliability assessment.
Fortuna G; Chainani-Wu N; Lozada-Nur F; Aria M; Cepeda-Valdes R; Pollio A; Marinkovich MP; Martinez-Salazar AE; Mignogna MD; Bruckner AL; Salas-Alanís JC
J Am Acad Dermatol; 2013 Jan; 68(1):83-92. PubMed ID: 22575158
[TBL] [Abstract][Full Text] [Related]
10. The severity of malnutrition in children with epidermolysis bullosa correlates with disease severity.
Manjunath S; Mahajan R; De D; Handa S; Attri S; Behera BN; Bhasin SL; Bolia R
Sci Rep; 2021 Aug; 11(1):16827. PubMed ID: 34413404
[TBL] [Abstract][Full Text] [Related]
11. The Birmingham Epidermolysis Bullosa Severity score: development and validation.
Moss C; Wong A; Davies P
Br J Dermatol; 2009 May; 160(5):1057-65. PubMed ID: 19434791
[TBL] [Abstract][Full Text] [Related]
12. Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese.
Cestari T; Prati C; Menegon DB; Prado Oliveira ZN; Machado MC; Dumet J; Nakano J; Murrell DF
Int J Dermatol; 2016 Feb; 55(2):e94-9. PubMed ID: 26474322
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
[TBL] [Abstract][Full Text] [Related]
14. Patterns of oral mucosa lesions in patients with epidermolysis bullosa: comparison and agreement between oral medicine and dermatology.
Fortuna G; Lozada-Nur F; Pollio A; Aria M; Cepeda-Valdes R; Marinkovich MP; Bruckner AL; Salas-Alanís JC
J Oral Pathol Med; 2013 Nov; 42(10):733-40. PubMed ID: 23772832
[TBL] [Abstract][Full Text] [Related]
15. Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa.
Esposito S; Guez S; Orenti A; Tadini G; Scuvera G; Corti L; Scala A; Biganzoli E; Berti E; Principi N
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669234
[TBL] [Abstract][Full Text] [Related]
16. Birmingham epidermolysis severity score and vitamin D status are associated with low BMD in children with epidermolysis bullosa.
Rodari G; Guez S; Manzoni F; Chalouhi KK; Profka E; Bergamaschi S; Salera S; Tadini G; Ulivieri FM; Spada A; Giavoli C; Esposito S
Osteoporos Int; 2017 Apr; 28(4):1385-1392. PubMed ID: 28012019
[TBL] [Abstract][Full Text] [Related]
17. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.
Jain SV; Harris AG; Su JC; Orchard D; Warren LJ; McManus H; Murrell DF
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):692-698. PubMed ID: 27580431
[TBL] [Abstract][Full Text] [Related]
18. Validation and Repeatability of the Epidermolysis Bullosa Eye Disease Index in Dystrophic Epidermolysis Bullosa.
Chen VM; Kumar VSS; Noh E; Perloff J
Cornea; 2023 Jan; 42(1):74-79. PubMed ID: 36197337
[TBL] [Abstract][Full Text] [Related]
19. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument.
Frew JW; Martin LK; Nijsten T; Murrell DF
Br J Dermatol; 2009 Dec; 161(6):1323-30. PubMed ID: 19681875
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine metabolism in children and adolescents with epidermolysis bullosa.
De Giuseppe R; Venturelli G; Guez S; Salera S; De Vita C; Consonni D; Dellanoce C; Bamonti F; Chiarelli G; Manzoni F; Maiavacca R; Esposito S
BMC Pediatr; 2016 Oct; 16(1):173. PubMed ID: 27793182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
